ESA Closes Investigation into Alleged Market Sharing in the Retail Pharmaceutical Market

The EFTA Surveillance Authority (ESA) has decided to close its investigation into alleged market sharing in the retail pharmaceutical market relating to the activities of Lyfjaval ehf.

According to ESA's announcement, a thorough analysis and assessment of the evidence led the Authority to conclude that there were no grounds for continuing the investigation.

Mörkin Law Firm represented the interests of SKEL Investment Company hf., the majority shareholder of Drangar hf., the parent company of Lyfjaval ehf., in connection with the investigation. The case was unique in several respects, not least because ESA's unannounced inspection at Lyfjaval was the first of its kind conducted in Iceland.

The matter was handled by Einar Þór Sverrisson and Hildur Leifsdóttir.